Cytomos is pioneering a new, label-free single-cell, cytometry technology based on dielectric spectroscopy, which measures the refraction of an electric field at material interfaces in and around individual cells.  By increasing the analysis frequency more specific information can be measured from each individual cell e.g.  cell size, membrane characteristics and organelle density.   This potentially disruptive technology encompasses 1) microchip-integrated sensors providing unprecedented levels of cell sensitivity across 16,000 frequencies per cell and 2) powerful machine learning algorithms capable of revealing more information about cells and cell populations within a sample. 

The intrinsic nature of our technology enables fast, unbiased sample assessment as no labelling or other extrinsic manipulation of cells is required and so, unlike conventional methods, Cytomos technology provides a holistic view of cellular events at the single-cell level. It measures properties intrinsic to the cell itself and it is not dependent upon arbitrary extrinsic markers. Our technology can therefore become part of drug screening cascades and phenotypically characterise cell changes in response to a treatment when the precise target and/or mechanism of action is not known. 

Furthermore, Cytomos technology has the potential to analyse patient-derived cells for a better prediction of disease state and/or therapeutic outcomes, allowing patients to receive the correct diagnosis and most effective drug for their treatment. This information could then be back translated into drug screening programmes and ensure reduce attrition rates early on in the lead optimisation phase of drug development.